Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas
Shoukat Afshar-Sterle, Dimitra Zotos, Nicholas J Bernard, Anna K Scherger, Lisa Roedling, Amber E Alsop, Jennifer Walker, Frederick Masson, Gabrielle T Belz, Lynn M Corcoran, Lorraine A O'Reilly, Andreas Strasser, Mark J Smyth, Ricky Johnstone, David M Tarlinton, Stephen L Nutt, Axel Kallies
Nature Medicine | NATURE PUBLISHING GROUP | Published : 2014
We thank L. Pasqualucci (Columbia University) for Bcl6-transgenic mice, D. Yu (Monash University) for Cd28<SUP>-/-</SUP> mice, M. Reth (Albert-Ludwigs-Universitat) for Cd79a-Cre mice, L. Wu (Walter and Eliza Hall Institute of Medical Research (WEHI)) for MHC-I antibodies and A. Brooks (University of Melbourne) for antibodies, D. Gray (WEHI) for TCR antibodies, J. Markham for help with the statistical analysis, and P. Schneider (University of Lausanne) for the Fc-FasL. This work was supported by grants and fellowships from the National Health and Medical Research Council of Australia (G.T.B., L.M.C., S.L.N., D.M.T., A.K., A.S., M.J.S. and L.A.O.), the Australia Research Council (A.K., S.L.N.), the Sylvia and Charles Viertel Foundation and the Howard Hughes Medical Institute (A.K., G.T.B.), the Cancer Council Victoria (D.Z.), Cancer Australia and the Cancer Council New South Wales (L.A.O.), and the Leukemia & Lymphoma Society (A.K., L.A.O. and A.S.). This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support scheme.